OKYO OKYO Pharma

OKYO Pharma Limited ("OKYO" or the "Company") - Result of the Annual General Meeting

OKYO Pharma Limited ("OKYO" or the "Company") - Result of the Annual General Meeting

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

LONDON, Sept. 25, 2020 (GLOBE NEWSWIRE) -- OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that at the annual general meeting (the “Annual General Meeting”) held earlier today the proposed resolutions set out in the notice of Annual General Meeting dated 9 September 2020 were duly passed.

The results of the proxy voting will be available shortly on the Company's website, .

The person who arranged for the release of this announcement on behalf of the Company was Keeren Shah, Chief Financial Officer of OKYO.

About OKYO

OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.

Enquiries:

OKYO Pharma LimitedWilly Simon+44 (0)20 7382 8300
   
Optiva Securities Limited



Robert Emmet+44 (0)20 3981 4173

For further information, please visit the Company's website at

EN
25/09/2020

Underlying

OKYOOKYO Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OKYO Pharma

 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma to Ring the Opening Bell at Nasdaq

OKYO Pharma to Ring the Opening Bell at Nasdaq LONDON and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: ), a clinical-stage biopharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, announced that Executive Chairman and Founder, Gabriele Cerrone and the OKYO management team will ring the Opening Bell at the Nasdaq MarketSite in Times Square, New York today. The ceremony will be held from 9:15 AM to 9:45 AM E...

6h / 41m 1 EN
 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma Announces Chairman and Founder Acquires Shares

OKYO Pharma Announces Chairman and Founder Acquires Shares LONDON and NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 24,551 of the Company’s ordinary shares ...

December 15, 2025 1 EN
 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcome...

OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain Patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in nerve fiber count and fiber length, trends not observed in the placebo groupThese findings suggest that urcosimod may have a positive impact on corneal nerve health in patients with neuropathic corneal painCorneal nerve imaging data from the Phase 2 NCP trial were analyzed using in vivo confocal microscopy LONDON and NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (N...

December 11, 2025 1 EN
 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma Announces Chairman and Founder Acquires Shares

OKYO Pharma Announces Chairman and Founder Acquires Shares LONDON and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces that Panetta Partners Limited, an entity in which Gabriele Cerrone, Executive Chairman has a beneficial interest, has acquired 27,051 of the Company’s ordinary shares on NASDAQ, bringing his to...

December 3, 2025 1 EN
 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma Announces Chairman and Founder Acquires Shares

OKYO Pharma Announces Chairman and Founder Acquires Shares LONDON and NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces that Panetta Partners Limited, an entity in which Gabriele Cerrone, Executive Chairman has a beneficial interest, has acquired 82,018 of the Company’s ordinary shares on NASDAQ, bringing his to...

November 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch